1
|
Danishevich A, Bilyalov A, Nikolaev S, Khalikov N, Isaeva D, Levina Y, Makarova M, Nemtsova M, Chernevskiy D, Sagaydak O, Baranova E, Vorontsova M, Byakhova M, Semenova A, Galkin V, Khatkov I, Gadzhieva S, Bodunova N. CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes. Biomedicines 2023; 11:3343. [PMID: 38137564 PMCID: PMC10741544 DOI: 10.3390/biomedicines11123343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 12/10/2023] [Accepted: 12/12/2023] [Indexed: 12/24/2023] Open
Abstract
Malignant neoplasms, including pancreatic cancer and melanoma, are major global health challenges. This study investigates melanoma pancreatic syndrome, a rare hereditary tumor syndrome associated with CDKN2A gene mutations. CDKN2A mutations contribute to a lifetime risk of melanoma ranging from 28% to 67%. This study reports the clinical features of six individuals with CDKN2A mutations and identifies recurrent alterations such as c.307_308del, c.159G>C and c.71G>C. It highlights the need for CDKN2A mutation testing in suspected cases of familial atypical multiple mole melanoma. Clinically significant variants show associations with melanoma and pancreatic cancer. The challenges of treating individuals with CDKN2A mutations are discussed, and the lack of specific targeted therapies is highlighted. Preclinical studies suggest a potential benefit of CDK4/6 inhibitors, although clinical trials show mixed results. This study underscores the importance of continued research into improved diagnostic and therapeutic strategies to address the complexities of hereditary cancer syndromes.
Collapse
Affiliation(s)
- Anastasiia Danishevich
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| | - Airat Bilyalov
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia
| | - Sergey Nikolaev
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| | - Nodirbec Khalikov
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| | - Daria Isaeva
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| | - Yuliya Levina
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| | - Maria Makarova
- LLC Evogen, 115191 Moscow, Russia
- Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology, Ministry of Healthcare of the Russian Federation, 117997 Moscow, Russia
| | - Marina Nemtsova
- LLC Evogen, 115191 Moscow, Russia
- Research Centre for Medical Genetics of N.P. Bochkov, 115522 Moscow, Russia
- Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, Ministry of Health of Russian Federation, 119991 Moscow, Russia
| | - Denis Chernevskiy
- LLC Evogen, 115191 Moscow, Russia
- FSBEI HE “Privolzhsky Research Medical University”, Ministry of Health of Russian Federation, 603950 Nizhny Novgorod, Russia
| | - Olesya Sagaydak
- LLC Evogen, 115191 Moscow, Russia
- Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia
| | - Elena Baranova
- LLC Evogen, 115191 Moscow, Russia
- Russian Medical Academy of Continuous Professional Education, Russia, 125993 Moscow, Russia
| | - Maria Vorontsova
- Faculty of Medicine, Lomonosov Moscow State University, 119991 Moscow, Russia
- The National Medical Research Center for Endocrinology, 117292 Moscow, Russia
| | - Mariya Byakhova
- Moscow Healthcare Department, Moscow State Budgetary Healthcare Institution Moscow City Oncological Hospital No. 1, 117152 Moscow, Russia
| | - Anna Semenova
- Moscow Healthcare Department, Moscow State Budgetary Healthcare Institution Moscow City Oncological Hospital No. 1, 117152 Moscow, Russia
| | - Vsevolod Galkin
- Moscow Healthcare Department, Moscow State Budgetary Healthcare Institution Moscow City Oncological Hospital No. 1, 117152 Moscow, Russia
| | - Igor Khatkov
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| | | | - Natalia Bodunova
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia (N.K.); (D.I.)
| |
Collapse
|
2
|
Leuschner G, Semenova A, Mayr CH, Kapellos TS, Ansari M, Seeliger B, Frankenberger M, Kneidinger N, Hatz RA, Hilgendorff A, Prasse A, Behr J, Mann M, Schiller HB. Mass spectrometry-based autoimmune profiling reveals predictive autoantigens in idiopathic pulmonary fibrosis. iScience 2023; 26:108345. [PMID: 38026226 PMCID: PMC10661358 DOI: 10.1016/j.isci.2023.108345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 09/13/2023] [Accepted: 10/23/2023] [Indexed: 12/01/2023] Open
Abstract
Autoimmunity plays a role in certain types of lung fibrosis, notably connective tissue disease-associated interstitial lung disease (CTD-ILD). In idiopathic pulmonary fibrosis (IPF), an incurable and fatal lung disease, diagnosis typically requires clinical exclusion of autoimmunity. However, autoantibodies of unknown significance have been detected in IPF patients. We conducted computational analysis of B cell transcriptomes in published transcriptomics datasets and developed a proteomic Differential Antigen Capture (DAC) assay that captures plasma antibodies followed by affinity purification of lung proteins coupled to mass spectrometry. We analyzed antibody capture in two independent cohorts of IPF and CTL-ILD patients over two disease progression time points. Our findings revealed significant upregulation of specific immunoglobulins with V-segment bias in IPF across multiple cohorts. We identified a predictive autoimmune signature linked to reduced transplant-free survival in IPF, persisting over time. Notably, autoantibodies against thrombospondin-1 were associated with decreased survival, suggesting their potential as predictive biomarkers.
Collapse
Affiliation(s)
- Gabriela Leuschner
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
- Department of Internal Medicine V, Ludwig-Maximilian University Munich, CPC-M bioArchive, Munich, Asklepios Clinics, Gauting, Germany
| | - Anna Semenova
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Christoph H. Mayr
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Theodore S. Kapellos
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Meshal Ansari
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Benjamin Seeliger
- Department of Pneumology, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany
| | - Marion Frankenberger
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
- Department of Internal Medicine V, Ludwig-Maximilian University Munich, CPC-M bioArchive, Munich, Asklepios Clinics, Gauting, Germany
| | - Nikolaus Kneidinger
- Department of Internal Medicine V, Ludwig-Maximilian University Munich, CPC-M bioArchive, Munich, Asklepios Clinics, Gauting, Germany
| | - Rudolf A. Hatz
- Center for Thoracic Surgery Munich, Ludwig-Maximilians-University of Munich (LMU), Munich, and Asklepios Medical Center, Member of the German Center for Lung Research (DZL), Gauting, Germany
| | - Anne Hilgendorff
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
- Center for Comprehensive Developmental Care (CDeCLMU), Hospital of the Ludwig-Maximilians University (LMU), Member of the German Center for Lung Research (DZL), CPC-M bioArchive, Munich, Germany
| | - Antje Prasse
- Department of Pneumology, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany
| | - Jürgen Behr
- Department of Internal Medicine V, Ludwig-Maximilian University Munich, CPC-M bioArchive, Munich, Asklepios Clinics, Gauting, Germany
| | - Matthias Mann
- Max Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, Martinsried, Germany
| | - Herbert B. Schiller
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
- Institute of Experimental Pneumology, LMU University Hospital, Ludwig-Maximilians University, Munich, Germany
| |
Collapse
|
3
|
Rosenberger FA, Thielert M, Strauss MT, Schweizer L, Ammar C, Mädler SC, Metousis A, Skowronek P, Wahle M, Madden K, Gote-Schniering J, Semenova A, Schiller HB, Rodriguez E, Nordmann TM, Mund A, Mann M. Spatial single-cell mass spectrometry defines zonation of the hepatocyte proteome. Nat Methods 2023; 20:1530-1536. [PMID: 37783884 PMCID: PMC10555842 DOI: 10.1038/s41592-023-02007-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 08/15/2023] [Indexed: 10/04/2023]
Abstract
Single-cell proteomics by mass spectrometry is emerging as a powerful and unbiased method for the characterization of biological heterogeneity. So far, it has been limited to cultured cells, whereas an expansion of the method to complex tissues would greatly enhance biological insights. Here we describe single-cell Deep Visual Proteomics (scDVP), a technology that integrates high-content imaging, laser microdissection and multiplexed mass spectrometry. scDVP resolves the context-dependent, spatial proteome of murine hepatocytes at a current depth of 1,700 proteins from a cell slice. Half of the proteome was differentially regulated in a spatial manner, with protein levels changing dramatically in proximity to the central vein. We applied machine learning to proteome classes and images, which subsequently inferred the spatial proteome from imaging data alone. scDVP is applicable to healthy and diseased tissues and complements other spatial proteomics and spatial omics technologies.
Collapse
Affiliation(s)
- Florian A Rosenberger
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Marvin Thielert
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Maximilian T Strauss
- Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Lisa Schweizer
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Constantin Ammar
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Sophia C Mädler
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Andreas Metousis
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Patricia Skowronek
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Maria Wahle
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Katherine Madden
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Janine Gote-Schniering
- Comprehensive Pneumology Center (CPC) / Institute of Lung Health and Immunity (LHI), Helmholtz Munich; Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Anna Semenova
- Comprehensive Pneumology Center (CPC) / Institute of Lung Health and Immunity (LHI), Helmholtz Munich; Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Herbert B Schiller
- Comprehensive Pneumology Center (CPC) / Institute of Lung Health and Immunity (LHI), Helmholtz Munich; Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Edwin Rodriguez
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Thierry M Nordmann
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
| | - Andreas Mund
- Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Matthias Mann
- Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
- Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
4
|
Sychov M, Eruzin A, Semenova A, Katashev P, Mjakin S, Zhukov MV, Aglikov A, Nosonovsky M, Skorb EV. Deposition of Nanostructured Tungsten Oxide Layers by a New Method: Periodic Modulation of the Deposition Angle. Langmuir 2023; 39:12336-12345. [PMID: 37603287 DOI: 10.1021/acs.langmuir.3c01290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/22/2023]
Abstract
Periodic modulation of the deposition angle (PMDA) is a new method to deposit nanostructured and continuous layers with controllable periodic density fluctuation. The method is used for the magnetron sputtering of a WO3 layer for an electrochromic device (ECD). An experimental study indicates that the electrochromic coloration-bleaching rate nearly doubles and the electrochromic efficiency grows by about 25% in comparison with the traditional method. The ECD efficiency rises with the increasing degree of nanostructure ordering, surface roughness, and homogeneity of the WO3 layer. The method is promising for coating deposition techniques needed to produce versatile devices with specific requirements for ion transport in surface layers, coatings, and interfaces, such as fuel cells, batteries, and supercapacitors.
Collapse
Affiliation(s)
- Maxim Sychov
- St. Petersburg State Institute of Technology, 26 Moskovski Ave, St. Petersburg 190013, Russia
- Institute of Silicate Chemistry, Russian Academy of Science, St. Petersburg, 199034 Russia
- National Research Center "Kurchatov Institute" - Central Research Institute of Structural Materials "Prometey″, St. Petersburg, 191015 Russia
| | - Alexander Eruzin
- St. Petersburg State Institute of Technology, 26 Moskovski Ave, St. Petersburg 190013, Russia
| | - Anna Semenova
- St. Petersburg State Institute of Technology, 26 Moskovski Ave, St. Petersburg 190013, Russia
| | - Pavel Katashev
- St. Petersburg State Institute of Technology, 26 Moskovski Ave, St. Petersburg 190013, Russia
| | - Sergey Mjakin
- St. Petersburg State Institute of Technology, 26 Moskovski Ave, St. Petersburg 190013, Russia
- Institute for Analytical Instrumentation, Russian Academy of Sciences, St. Petersburg 198095, Russia
| | - Mikhail V Zhukov
- Infochemistry Scientific Center, ITMO University, 9 Lomonosov St., St. Petersburg, 191002, Russia
| | - Aleksandr Aglikov
- Infochemistry Scientific Center, ITMO University, 9 Lomonosov St., St. Petersburg, 191002, Russia
| | - Michael Nosonovsky
- Infochemistry Scientific Center, ITMO University, 9 Lomonosov St., St. Petersburg, 191002, Russia
- University of Wisconsin─Milwaukee, 3200 N Cramer St., Milwaukee, Wisconsin 53210, United States
| | - Ekaterina V Skorb
- Infochemistry Scientific Center, ITMO University, 9 Lomonosov St., St. Petersburg, 191002, Russia
| |
Collapse
|
5
|
Makarova M, Nemtsova M, Danishevich A, Chernevskiy D, Belenikin M, Krinitsina A, Baranova E, Sagaydak O, Vorontsova M, Khatkov I, Zhukova L, Bodunova N, Nikolaev S, Byakhova M, Semenova A, Galkin V, Gadzhieva S. The CFTR Gene Germline Heterozygous Pathogenic Variants in Russian Patients with Malignant Neoplasms and Healthy Carriers: 11,800 WGS Results. Int J Mol Sci 2023; 24:ijms24097940. [PMID: 37175647 PMCID: PMC10178054 DOI: 10.3390/ijms24097940] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 04/14/2023] [Accepted: 04/25/2023] [Indexed: 05/15/2023] Open
Abstract
More than 275 million people in the world are carriers of a heterozygous mutation of the CFTR gene, associated with cystic fibrosis, the most common autosomal recessive disease among Caucasians. Some recent studies assessed the association between carriers of CFTR variants and some pathologies, including cancer risk. The aim of this study is to analyze the landscape of germline pathogenic heterozygous CFTR variants in patients with diagnosed malignant neoplasms. For the first time in Russia, we evaluated the frequency of CFTR pathogenic variants by whole-genome sequencing in 1800 patients with cancer and compared this with frequencies of CFTR variants in the control group (1825 people) adjusted for age and 10,000 healthy individuals. In the issue, 47 out of 1800 patients (2.6%) were carriers of CFTR pathogenic genetic variants: 0.028 (42/1525) (2.8%) among breast cancer patients, 0.017 (3/181) (1.7%) among colorectal cancer patients and 0.021 (2/94) (2.1%) among ovarian cancer patients. Pathogenic CFTR variants were found in 52/1825 cases (2.85%) in the control group and 221 (2.21%) in 10,000 healthy individuals. Based on the results of the comparison, there was no significant difference in the frequency and distribution of pathogenic variants of the CFTR gene, which is probably due to the study limitations. Obviously, additional studies are needed to assess the clinical significance of the heterozygous carriage of CFTR pathogenic variants in the development of various pathologies in the future, particularly cancer.
Collapse
Affiliation(s)
- Maria Makarova
- LLC Evogen, 115191 Moscow, Russia
- Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology of the Ministry of Healthcare of the Russian Federation, 117997 Moscow, Russia
| | - Marina Nemtsova
- LLC Evogen, 115191 Moscow, Russia
- Research Centre for Medical Genetics of N.P. Bochkov, 115522 Moscow, Russia
- Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov of the Ministry of Health of Russian Federation, 119991 Moscow, Russia
| | | | | | | | | | - Elena Baranova
- LLC Evogen, 115191 Moscow, Russia
- Academy of Continuing Professional Education of the Ministry of Health of Russian Federation, 125993 Moscow, Russia
| | | | - Maria Vorontsova
- The National Medical Research Center for Endocrinology, 117292 Moscow, Russia
| | - Igor Khatkov
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia
| | - Lyudmila Zhukova
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia
| | - Natalia Bodunova
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia
| | - Sergey Nikolaev
- SBHI Moscow Clinical Scientific Center Named after Loginov MHD, 111123 Moscow, Russia
| | - Mariya Byakhova
- City Clinical Oncological Hospital No. 1, Moscow Department of Healthcare, 117152 Moscow, Russia
| | - Anna Semenova
- City Clinical Oncological Hospital No. 1, Moscow Department of Healthcare, 117152 Moscow, Russia
| | - Vsevolod Galkin
- City Clinical Oncological Hospital No. 1, Moscow Department of Healthcare, 117152 Moscow, Russia
| | - Saida Gadzhieva
- City Clinical Oncological Hospital No. 1, Moscow Department of Healthcare, 117152 Moscow, Russia
| |
Collapse
|
6
|
Byron N, Semenova A, Sakata S. Mutual Interactions between Brain States and Alzheimer's Disease Pathology: A Focus on Gamma and Slow Oscillations. Biology (Basel) 2021; 10:707. [PMID: 34439940 PMCID: PMC8389330 DOI: 10.3390/biology10080707] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 07/17/2021] [Accepted: 07/21/2021] [Indexed: 12/26/2022]
Abstract
Brain state varies from moment to moment. While brain state can be defined by ongoing neuronal population activity, such as neuronal oscillations, this is tightly coupled with certain behavioural or vigilant states. In recent decades, abnormalities in brain state have been recognised as biomarkers of various brain diseases and disorders. Intriguingly, accumulating evidence also demonstrates mutual interactions between brain states and disease pathologies: while abnormalities in brain state arise during disease progression, manipulations of brain state can modify disease pathology, suggesting a therapeutic potential. In this review, by focusing on Alzheimer's disease (AD), the most common form of dementia, we provide an overview of how brain states change in AD patients and mouse models, and how controlling brain states can modify AD pathology. Specifically, we summarise the relationship between AD and changes in gamma and slow oscillations. As pathological changes in these oscillations correlate with AD pathology, manipulations of either gamma or slow oscillations can modify AD pathology in mouse models. We argue that neuromodulation approaches to target brain states are a promising non-pharmacological intervention for neurodegenerative diseases.
Collapse
Affiliation(s)
- Nicole Byron
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK
| | - Anna Semenova
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK
| | - Shuzo Sakata
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK
| |
Collapse
|
7
|
Shendaleva N, Novik AV, Zozulya A, Nekhaeva TL, Semenova A, Teletaeva GM, Latipova DK, Semiglazova T, Protsenko S, Baldueva IA. Impact of the azoximer bromide concomitant therapy on patient outcomes in patients with melanoma. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e21574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21574 Background: Immunomodulators are used in the treatment of patients with melanoma. However, their role as anticancer therapeutic agents requires further investigation. Azoximer bromide (AB) is a well-tolerated immunomodulator that has been used in cases of melanoma. We investigated the impact of AB when used concomitantly with other melanoma treatment modalities on the overall survival (OS) and time to progression (TTP). Methods: We reviewed per protocol, a single-center real practice database that included 1,391 patients. Forty-two patients had received AB as a concomitant therapeutic agent. Concomitant medications included immune checkpoint inhibitors, cytokines, vaccines, targeted therapy and surgery alone in the adjuvant or metastatic setting. We built Cox proportional-hazards models for OS and TTP stratified by stage in SPSS v19. All known prognostic factors (LDH, TNM stage and sub-stage, mutations, sex, age, therapy by type, and by immunologic action) were included in the model along with AB therapy. Known factors were separated from unknown (AB therapy) by different variable blocks. A step forward method was used for model construction. Results: Significant (p < 0.05) factors to emerge in the OS model were LDH (Hazards ration [HR]: 1.458 for high LDH), sub-stage (HR: 1.718 for M1b-d sub-stage), BRAF mutation (HR: 0.698 if present), current therapy type (HR: 0.501 for immune checkpoint inhibitors (ICI), HR: 0.656 for targeted therapy (TT), HR: 1.275 for systemic immunotherapy, HR: 0.825 per added method for complex treatment, HR: 0.605 for surgery), previous treatment (HR: 0.778 for ICI, HR: 1.207 for single-agent chemotherapy, HR 1.176 for targeted or local treatment, HR: 1.315 for combination chemotherapy, HR: 2.039 for immunosuppressive factors reduction methods), male sex (HR: 1.204) and AB therapy (HR: 0.475). Significant factors in the TTP model were LDH (HR: 1.348 for high LDH), sub-stage (HR: 1.434 for B-D sub-stage), current therapy type (HR: 0.432 for (ICI), HR: 0.541 for TT, HR: 0.692 per added method for complex therapy HR: 0.705 for surgery), previous therapy (HR: 0.789 for ICI), male sex (HR: 1.167) and AB therapy (HR: 0.478). Conclusions: The addition of AB to standard therapy in melanoma appears to be an independent favorable prognostic factor. Prospective, randomized, clinical trials are needed to investigate these findings further.
Collapse
Affiliation(s)
- Natalya Shendaleva
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | | - Anton Zozulya
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | | - Anna Semenova
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | | | | - Tatiana Semiglazova
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | - Svetlana Protsenko
- N.N.Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | |
Collapse
|
8
|
Novik AV, Girdyuk DV, Nekhaeva TL, Emelyanova NV, Semenova A, Teletaeva GM, Latipova DK, Protsenko S, Baldueva IA. Progression prediction model for solid tumors with clinical and immunological parameters. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.2539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2539 Background: The immune system has well-known relation to tumor progression. Numerous immune-related parameters exist, but only a minor part could be used as biomarkers, especially dynamic ones. We trained a progression prediction model based on clinical features and peripheral immune system assessments. Methods: Patients with immunogenic (melanoma, 295, kidney cancer, 81), non-immunogenic (soft tissue sarcoma, 47, colorectal cancer, 26) and multiple primary tumors (29) with immunologic assessments before treatment (23.5%), on therapy (58.3), and in follow-up after the treatment (18.2%) were randomly divided in 7:3 ratio to the training and test groups. Counts of lymphocytes, T-, B, NK cells, cytotoxic lymphocytes, T-helpers were used as immunologic parameters. Age, sex, disease, stage, therapy, mutational status, last response on treatment, disease and therapy duration, previous treatments were used as clinical ones. The model was trained to predict disease progression in the next three months using “Catboost” gradient boosting. We used ROC AUC to test model performance and Yoden’s index for optimal cutoff calculation. We also studied the influence of model prediction on overall survival (OS) and time to progression (TTP) on the test dataset using the Kaplan-Meyer method and Cox regression. Results: We used 1682 assessments of immune parameters (immune status, IS) done in 354 patients (average 5 per patient) to train the model and 616 IS in 124 patients for validation. All IS of one patient were in the same group. The ROC AUC value of the model was 0.801. The model prediction of progression increased the probability of progressive disease from 37.5 to 62% and decreased the response rate from 37,5% to 8.4% (p = 0.016). The model prediction did not add information over known prognostic factors for OS in the multifactorial model but was an independent prognostic factor for TTP (HR 2.204, p = 0.011). False-positive results separate the group of patients with poor prognosis (OS 16 months, TTP 6 months) among patients with clinical benefit from patients with favorable prognosis (OS 61 months, TTP 18 months, p < 0.001), who had a truly negative model prediction. The possibility of prognosis improvement with therapy change was an essential factor for OS and TTP prediction (р < 0.001). The model was useful in predicting higher OS in patients with disease progression (p = 0.033) and shorter response duration in patients with clinical benefit (р = 0.03). Conclusions: Our progression prediction model provides clinically useful information and can be used for decision making in several clinical situations. Its utility should be tested in a prospective trial.
Collapse
Affiliation(s)
| | | | | | | | - Anna Semenova
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | | | | - Svetlana Protsenko
- N.N.Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | |
Collapse
|
9
|
Novik AV, Shendaleva N, Zozulya A, Nekhaeva TL, Semenova A, Teletaeva GM, Latipova DK, Semiglazova T, Protsenko S, Baldueva IA. Impact of the azoximer bromide concomitant therapy on outcomes in patients with soft tissue sarcoma. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e23534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e23534 Background: Immunomodulators are used in the management of patients with soft tissue sarcoma, (STS). However, the precise mechanism behind their benefits in anticancer therapy effects have yet to be determined. We assessed the impact of the immunomodulator azoximer bromide (AB) as a prognostic factor for survival when used concomitant with standard therapy in patients with STS. Methods: We reviewed medical history and disease outcomes in STS patients attending the Petrov National Medical Research Centre of Oncology (St Petersburg, Russia). Data were collected per protocol on treatments and patient outcomes. A Cox proportional-hazards model for time-to-progression (TTP) was constructed in SPSS v19. Known prognostic factors (TNM stage and substage, sex, age, therapy by type, and by immunologic action, as well as treatment modality), setting and AB therapy extracted from patient records were included in the model. The model employed a ‘step-forward’ method with AB therapy identified as the ‘unknown’ variable. Results: Complete patient records were available on 243 clinic attendees (from 2010 to 2020), 25 had received treatment with AB. The median follow-up was 20.9 months. Patients received single- and multi-agent chemotherapy, vaccines, cytokines, radiation therapy and/or surgery in the adjuvant or metastatic setting. Significant factors in the TTP model were current therapy type (Hazards ratios: 0.59 for surgery, 0.533 per added method for complex therapy and HR 1.689 for single-agent chemotherapy), previous systemic chemotherapy (HR: 1.451) and AB therapy (HR 0.547). Conclusions: Use of AB with standard therapy in STS emerged as an independent favorable prognostic factor. Appropriately controlled, well-designed prospective trials are needed to investigate this finding further. [Table: see text]
Collapse
Affiliation(s)
| | - Natalya Shendaleva
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | - Anton Zozulya
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | | - Anna Semenova
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | | | | - Tatiana Semiglazova
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | - Svetlana Protsenko
- N.N.Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
| | | |
Collapse
|
10
|
Belich N, Udalova N, Semenova A, Petrov A, Fateev S, Tarasov A, Goodilin E. Perovskite Puzzle for Revolutionary Functional Materials. Front Chem 2020; 8:550625. [PMID: 33240840 PMCID: PMC7667269 DOI: 10.3389/fchem.2020.550625] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Accepted: 08/28/2020] [Indexed: 11/13/2022] Open
Abstract
Widely spread crystal lattices of perovskites represent a natural flexible platform for chemical design of various advanced functional materials with unique features. An interplay between chemical bonding, defects and crystallochemical peculiarities makes the perovskite structure a "LEGO designer" utilizing natural features of chemical elements of the renowned Mendeleev's Periodic Table (PTE) celebrating its 150-year anniversary. In this mini-review, crystal chemistry and bonding features, physical and functional properties, preparation methods and tuning functional properties with periodicity "tools" of the PTE will be exemplified for legendary families of high-temperature superconductive cuprates, colossal magnetoresistive manganites and hybrid lead halides for a new generation of solar cells.
Collapse
Affiliation(s)
- Nikolai Belich
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia
| | - Natalia Udalova
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia
| | - Anna Semenova
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia
| | - Andrey Petrov
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia
| | - Sergey Fateev
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia
| | - Alexey Tarasov
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia.,Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| | - Eugene Goodilin
- Department of Materials Science, Lomonosov Moscow State University, Moscow, Russia.,Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
11
|
Jansson A, Klais‐Peets R, Grinienė E, Rubene G, Semenova A, Lewandowska A, Engström‐Öst J. Functional shifts in estuarine zooplankton in response to climate variability. Ecol Evol 2020; 10:11591-11606. [PMID: 33144986 PMCID: PMC7593182 DOI: 10.1002/ece3.6793] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 07/09/2020] [Accepted: 07/14/2020] [Indexed: 11/12/2022] Open
Abstract
Functional traits are becoming more common in the analysis of marine zooplankton community dynamics associated with environmental change. We used zooplankton groups with common functional properties to assess long-term trends in the zooplankton caused by certain environmental conditions in a highly eutrophicated gulf.Time series of zooplankton traits have been collected since the 1960s in the Gulf of Riga, Baltic Sea, and were analyzed using a combination of multivariate methods (principal coordinate analysis) and generalized additive models.One of the most significant changes was the considerable increase in the amount of the zooplankton functional groups (FGR) in coastal springtime communities, and dominance shifts from more complex to simpler organism groups-cladocerans and rotifers.The results also show that functional trait organism complexity (body size) decreased considerably due to cladoceran and rotifer increase following elevated water temperature. Salinity and oxygen had negligible effects on the zooplankton community.
Collapse
Affiliation(s)
- Anna Jansson
- Novia University of Applied SciencesEkenäsFinland
| | | | | | - Gunta Rubene
- Fish Resources Research DepartmentInstitute of Food Safety, Animal Health and EnvironmentRigaLatvia
| | - Anna Semenova
- Atlantic Branch of ‘Russian Federal Research Institute of Fisheries and Oceanography’ (AtlantNIRO)KaliningradRussia
| | | | | |
Collapse
|
12
|
Tsimafeyeu I, Gafanov R, Semenova A, Oganesyan A, Bondarenko A, Safina S, Zakurdaeva K, Protsenko S. Abstract A1: Clinical outcomes in patients with chronic hepatitis C and metastatic renal cell carcinoma (mRCC) after treatment with nivolumab. Cancer Immunol Res 2020. [DOI: 10.1158/2326-6074.tumimm19-a1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Clinical trials of immune checkpoint inhibitors have historically excluded patients with chronic hepatitis C (HCV) infection. The safety and efficacy profile of nivolumab is unknown in this under-represented population. Data were collected in a retrospective fashion on 36 patients with metastatic clear-cell mRCC. Patients were required to have a chronic HCV infection, no evidence of other malignancy or cirrhosis, and to have received nivolumab (3 mg/kg every 2 weeks) as second- or third-line therapy. Clinical outcomes included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Safety was evaluated. Median follow-up was 17.5 months. Nivolumab was well tolerated in all HCV-infected patients (grade 3-4 toxicity was found in 6 of 36 cases [17%]). No unexpected toxicity was observed. Exposure to nivolumab was not associated with increased risk for hepatocellular carcinoma and cirrhosis (N=0). Medians OS and PFS were 23.9 (95% CI 20.7-26.5) and 6.8 (95% CI 4.9-8.7) months, respectively. 23% of patients had partial responses. The efficacy and safety profile observed in this study supports the administration of nivolumab in mRCC patients infected with HCV and warrants further investigation.
Citation Format: Ilya Tsimafeyeu, Rustem Gafanov, Anna Semenova, Ani Oganesyan, Anastasia Bondarenko, Sufia Safina, Kristina Zakurdaeva, Svetlana Protsenko. Clinical outcomes in patients with chronic hepatitis C and metastatic renal cell carcinoma (mRCC) after treatment with nivolumab [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr A1.
Collapse
Affiliation(s)
| | - Rustem Gafanov
- 2Russian Scientific Center of Roentgenoradiology, Moscow, Russia,
| | - Anna Semenova
- 3N.N. Petrov Institute of Oncology, St. Petersburg, Russia,
| | - Ani Oganesyan
- 3N.N. Petrov Institute of Oncology, St. Petersburg, Russia,
| | | | - Sufia Safina
- 5Republic Clinical Cancer Center, Kazan, Russia,
| | | | | |
Collapse
|
13
|
Novik AV, Danilova AB, Baldueva IA, Sluzhev MI, Nehaeva TL, Larin S, Protsenko S, Semenova A, Danilov AO, Moiseyenko V, Georgiev GP. Long-term survival in patients (pts) with locally advanced or disseminated malignant melanoma (MM) or renal cell carcinoma (RCC), treated with tag-7 gene-modified (GMV) tumor cells: A phase II trial. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e14022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14022 Background: Immunotherapy may produce long lasting effects on survival.Magnitude of efficacy may be depended from immune factors. We evaluated the overall survival (OS) in pts treated with GMV with biomarker analysis of immunosuppressive factors (ISF) production by their tumor cells. Methods: Since 2001 to 2014 80 pts received GMV: 68 with MM and 12 pts with RCC. Treatment was given in the metastatic setting in 61 pts (MM-51, RCC – 10) and in the adjuvant (after complete cytoreduction) setting in 19 pts (MM-17, RCC-2). Stage 3 was in 26 (33%) pts, stage 4 in 54 (67%). Pt’s tumor samples were transferred to culture, transfected with TAG7and inactivated by radiation. Produced product was injected SC every 3 weeks until progression or 2y of therapy. ISF (MICA, TGF-β1, IL-10 and VEGF) were measured in the supernatants of the tumor cell cultures and used as predictive factors. Results: The 5-yr OS in intention to treat population was 25.1%. There was no differences in MM and RCC OS (Log-rank p = 0.44). Median OS in metastatic setting was 0,7 y, in adjuvant – 3,1 y. Classification trees were built on the basis of ISF production. The median OS was 6.6 y in favorable prognosis (FP) group (MICA level ≤582 pg/ml, n = 15), 4.6 mo in unfavorable (UF) group (MICA level > 582 pg/ml, n = 12) (p < 0.0001). No significant differences were found between classification trees based on the other ISF (TGF-β1, IL-10 and VEGF). In stage 3-4 MM pts with FP median OS was 2,3 y with 31% pts alive in 10y, in UF group – 0,4 y; log-rank p = 1,94E-5. No FP pts received modern immunotherapy. Conclusions: GMV shows high results in carefully selected pts with low ISF production. Method should be further investigated in pts with FP. [Table: see text]
Collapse
Affiliation(s)
- Alexey Viktorovich Novik
- "National Medical Research Center of Oncology na N.N. Petrov" Ministry of Healthcare of Russian Federation, St Petersburg, Russian Federation
| | | | | | | | | | - Sergei Larin
- Institute of Gene Biology of the Russian Academy of Sciences, Moscow, Russian Federation
| | - Svetlana Protsenko
- N.N.Petrov Research Institute of Oncology, St. Petersburg, Russian Federation
| | - Anna Semenova
- N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
| | | | - Vladimir Moiseyenko
- Clinical and Research Center of Specialized Types of Medical Care (Oncological), St. Petersburg, Russian Federation
| | | |
Collapse
|
14
|
Semenova A, Guseva Y, Vaks V, Panin A, Babarina D, Morunova S, Vilkov A. THz absorption spectra of glucose and its polymers. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201819510011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Semenova A, Sergienko I, Ezhov M, Garcia-Giustiniani D, Monserrat L, Malakhov V, Popova A, Nozadze D, Kukharchuk V. The presence of pathogenic mutations in patients with definite or probable diagnosis of familial hypercholesterolemia defined by targeted next generation sequencing. Atherosclerosis 2017. [DOI: 10.1016/j.atherosclerosis.2017.06.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Lepkov S, Subortceva I, Tumyan G, Zejnalova P, Kolomejtsev O, Ryabukhina Y, Semenova A, Kokosadze N, Kupryshina N, Komarov I, Malikhova O, Ettinger O, Borisovskaya S, Lazarev I, Ivanova V, Ivashhenko R, Kemizh Y, Alla Kovrigina A, Nikitin I, Urvanceva O. PRIMARY EXTRANODAL NON-HODGKIN'S LYMPHOMA OF THE LIVER (PLL). Hematol Oncol 2017. [DOI: 10.1002/hon.2439_134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Lepkov
- Therapy; Russian National Research Medical University Named After N.I. Pirogov; Moscow Russian Federation
| | - I. Subortceva
- Hematology; Research Center For Haematology; Moscow Russian Federation
| | - G. Tumyan
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - P. Zejnalova
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - O. Kolomejtsev
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - Y. Ryabukhina
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - A. Semenova
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - N. Kokosadze
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - N. Kupryshina
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - I. Komarov
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - O. Malikhova
- Oncology; National Research Center For Oncology Named After N.N. Blochin; Moscow Russian Federation
| | - O. Ettinger
- Therapy; Russian National Research Medical University Named After N.I. Pirogov; Moscow Russian Federation
| | - S. Borisovskaya
- Therapy; Russian National Research Medical University Named After N.I. Pirogov; Moscow Russian Federation
| | - I. Lazarev
- Hematology; City Clinical Hospital Named After C.P. Botkin; Moscow Russian Federation
| | - V. Ivanova
- Hematology; City Clinical Hospital Named After C.P. Botkin; Moscow Russian Federation
| | - R. Ivashhenko
- Therapy; Clinical Hospital Named After V.M. Buyanov; Moscow Russian Federation
| | - Y. Kemizh
- Therapy; Clinical Hospital Named After V.M. Buyanov; Moscow Russian Federation
| | - A. Alla Kovrigina
- Hematology; Research Center For Haematology; Moscow Russian Federation
| | - I. Nikitin
- Therapy; Russian National Research Medical University Named After N.I. Pirogov; Moscow Russian Federation
| | - O. Urvanceva
- Therapy; Clinical Hospital Named After V.M. Buyanov; Moscow Russian Federation
| |
Collapse
|
17
|
Semenova A, Bombin D, Agapov V, Kostrykin M, Shigaev M. Tissue rSO2 management during cardiopulmonary bypass and ECMO. J Cardiothorac Vasc Anesth 2017. [DOI: 10.1053/j.jvca.2017.02.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
18
|
Semenova A, Agapov V, Evstifeev I, Shigaev M, Zhukov A. Trends of central and somatic rSO2 during cardiopulmonary bypass in adults and their interaction with cardiopulmonary bypass parameters. J Cardiothorac Vasc Anesth 2016. [DOI: 10.1053/j.jvca.2016.03.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
19
|
Semenova A, Agapov V, Shigaev M. Computer-assisted cardiopulmonary bypass: the possible way to improve safety. J Cardiothorac Vasc Anesth 2016. [DOI: 10.1053/j.jvca.2016.03.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
20
|
Ardura A, Zaiko A, Martinez JL, Samulioviene A, Semenova A, Garcia-Vazquez E. eDNA and specific primers for early detection of invasive species--A case study on the bivalve Rangia cuneata, currently spreading in Europe. Mar Environ Res 2015; 112:48-55. [PMID: 26453004 DOI: 10.1016/j.marenvres.2015.09.013] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Revised: 09/28/2015] [Accepted: 09/28/2015] [Indexed: 05/11/2023]
Abstract
Intense human activities facilitate the successful spread and establishment of non-indigenous aquatic organisms in marine and freshwater ecosystems. In some cases such intrusions result in noticeable and adverse changes in the recipient environments. In the Baltic Sea, the discovery and rapid initial spread of the North American wedge clam Rangia cuneata represents a new wave of invasion which may trigger unpredictable changes of the local benthic communities. In this study we present a species-specific DNA-based marker developed in silico and experimentally tested on environmental samples. Marker specificity and sensitivity were assessed in vitro from water samples containing different mixtures of the target species and other five bivalves currently present in the region: the native Cerastoderma glaucum, Macoma balthica and Mytilus trossulus, the invasive Dreissena polymorpha and the cryptogenic Mya arenaria. Cross-species amplification was not found in any case. The method allows to detecting at least 0.4 ng of R. cuneata DNA per μl, and 0.1 g of tissue per liter of water. Finally, the marker performance was assessed in water samples from the Baltic Sea and Vistula Lagoon. The coincidence between independent visual observations of R. cuneata and positive PCR amplification of the marker from the water samples confirmed the efficiency of this highly reproducible, fast, and technically easy method. R. cuneata traces can be detected from environmental DNA even when the population is sparse and small, enabling rapid management responses and allowing to track the invasion dynamics.
Collapse
Affiliation(s)
- Alba Ardura
- Department of Functional Biology, University of Oviedo, C/ Julian Claveria s/n, 33006 Oviedo, Spain; Marine Science and Technology Centre, Klaipeda University, H. Manto 84, LT 92294 Klaipeda, Lithuania.
| | - Anastasija Zaiko
- Marine Science and Technology Centre, Klaipeda University, H. Manto 84, LT 92294 Klaipeda, Lithuania; Coastal and Freshwater Group, Cawthron Institute, 98 Halifax Street East, 7010 Nelson, New Zealand.
| | - Jose L Martinez
- Unit of DNA Analysis, Scientific-Technical Services, University of Oviedo, Edificio Severo Ochoa, Campus del Cristo, 33006 Oviedo, Spain.
| | - Aurelija Samulioviene
- Marine Science and Technology Centre, Klaipeda University, H. Manto 84, LT 92294 Klaipeda, Lithuania.
| | - Anna Semenova
- Atlantic Research Institute of Marine Fisheries and Oceanography, Kaliningrad, Russia.
| | - Eva Garcia-Vazquez
- Department of Functional Biology, University of Oviedo, C/ Julian Claveria s/n, 33006 Oviedo, Spain.
| |
Collapse
|
21
|
Semenova A, Machinskaya RI, Lomakin DI. [The Influence of the Functional State of Brain Regulatory Structures on the Programming, Selective Regulation and Control of Cognitive Activity in Children. Report I: Neuropsychological and EEG Analysis of Age-Related Changes in Brain Regulatory Functions in Children Aged 9-12 Years]. Fiziol Cheloveka 2015; 41:5-17. [PMID: 26485784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Age-related changes in brain regulatory functions in children aged from 9 to 12 years with typical development were studied by means of neuropsychological and EEG analysis. The participants of the study were 107 children without learning difficulties and behavior deviations; they were devided into three groups (9-10, 10-11 and 11-12 years). The neuropsychological tests revealed nonlinear age-related changes in different executive brain functions. The group of 10-11-year-old children showed better results in programming, in- hibition of impulsive reactions and in the perception of socially relevant information than the group of 9-10- year-old children. At the same time, these children had more difficulties with selective activity regulation as compared with the younger group. The difficulties were mainly caused by switching from one element of the program to another and by retention of learned sequence of actions. These children also showed a lower level of motivation for task performance. The children aged 11-12 years had less difficulties with selective activity regulation; however, impulsive behavior was more frequent; these children also had a higher level of task performance motivation than in children aged 10-11 years. The analysis of resting state EEG revealed age-related differences in deviated EEG patterns associated with non-optimal functioning of fronto-thalamic system and hypothalamic structures. The incidence of these two types of EEG patterns was significantly higher in children aged 10-11 years as compared with children aged 9-10 years. The EEG of the groups of 10-11 and 11-12-years-old children did not show any significant differences.
Collapse
|
22
|
Semenova A, Nozadze D, Sergienko I, Vlasik T, Kukharchuk V. Lipoprotein-associated phospholipase A2 serum levels in patients from different categories of cardiovascular risk. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Kellerman D, Medvedeva N, Mukhina N, Semenova A, Baklanova I, Perelyaeva L, Gorshkov V. Vanadium doping of LiMnPO4: Vibrational spectroscopy and first-principle studies. Chem Phys Lett 2014. [DOI: 10.1016/j.cplett.2013.10.087] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Semenova A, Sergienko I, Masenko V, Kukharchuk V. Abstract: P970 THE INFLUENCE OF HIGH AND LOW ROSUVASTATIN DOSES ON ANGIOGENIC FACTORS SERUM LEVELS IN CORONARY ARTERY DISEASE PATIENTS. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71091-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|